Submit a poster abstract

The 5th Swiss Symposium in Point-of-Care Diagnostics on October 20, 2022 in Muttenz/Basel, Switzerland invites participants of the symposium to submit an abstract for the poster session. Unique in its format, the symposium and the poster presentations cover the full bandwidth of POC Diagnostics, from fundamental science and technology to new products and clinical adoption.

A prize will be awarded to the best poster (overall poster design and information). In addition, the scientific committee will select a few posters for oral short communication (presentation) as part of the symposium program.

Deadline for abstract submission is October 7, 2022 . Please fill out the template below and send your abstract to info@pocdx.ch. Authors of accepted abstracts will be informed and can then bring along their poster (A0 portrait format) to the symposium.

We are looking forward to your poster presentation,

The organizing committee.

Scientific Poster Session Jury

Eric Kübler (FHNW)
Denis Prim (HES-SO)
Felix Kurth (CSEM)
Jacky Weber (Bühlmann Labs)
Annalisa Macagno (Effectum Medical)

Poster abstracts 2022

#1

Direct, Label-free, and Multiplexed Biosensing by Scalable and Lithography-Free Metaplasmonic Surfaces for the Point-of-Care

Gerardo A. López-Muñoz (1,2) Javier Ramón-Azcón (1,3) and Artur Rydosz (1,2, 4)

1 Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Barcelona, Spain.
2 Institute of Electronics, AGH University of Science and Technology, Kraków, Poland.
3 ICREA- Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.

4 Advanced Diagnostic Equipment sp. z o.o., Krakow, Poland

Plasmonic metasurfaces have been widely widespread in the last years, motivated by the recent advances in the nanofabrication field and the increasing demand for high throughput biosensing platforms at the Point-of-Care. The recent advances in electronics, microfluidics, and signal processing have enabled the complete development of highly integrated prototypes for Point-of-Care applications. However, the progress observed from a fabrication point of view has been remarkable, led by the potential benefits metamaterials can offer in plasmonic sensing: sensor miniaturization, multiplexing opportunities, and extreme sensitivity biodetection. Although conventional top-down approaches, i.e., electron-beam lithography, have been extensively employed to develop plasmonic metasurfaces for biosensing, lithography-free bottom-up nanofabrication strategies based on nanopatterned thin-films by Glancing Angle Deposition (GLAD) and Thermal Dewetting (TDW) are candidates to surpass the limitations of top-down lithographic techniques with large-scale and high-throughput fabrication processes for 2D and 3D plasmonic metasurfaces over a broad material set. We focus on the challenges and opportunities to achieve lithography-free plasmonic metasurfaces by combining GLAD and TDW in single fabrication processes to conduct scalable and high-throughput plasmonic metamaterials for direct, sensitive, and multiplexed metaplasmonic biosensors for Point-of-Care applications.

 

#2

Implementation of rotational thromboelastometry in patients undergoing cardiac surgery

Isabel Rodríguez Martín

Clinical Biochemistry, Universidad de Sevilla, Spain.

Background: Perioperative coagulopathy and postoperative bleeding are the most common complications in patients undergoing cardiac surgery, especially when the cardiovascular surgery is associated with cardiopulmonary bypass (CPB). In this context, some studies suggest that implementation of viscoelastic point-of-care tests (POCT), such as rotational thromboelastometry (ROTEM , in conjunction with a specific algorithm for coagulation management, allow for better control of hemostatic pathology.

Methods: Retrospective cohort study including 675 patients who underwent cardiac surgery with cardiopulmonary bypass. The incidence of clinical postoperative complications were analyzed before and after ROTEM® implementation.

Results: Following viscoelastic testing and the implementation of a specific algorithm for coagulation management, the incidence of any allogeneic blood transfusion decreased (41.4% vs 31.9%, p=0.026) during the perioperative and postoperative period (26.5% vs 19.2%, p=0.061). In addition, significant reductions were detected in the incidence of heart disease (57.7% vs 55.8%, p=0.275; statistically significant reductions were detected in the incidenceof postoperative pericarditis (3.6% vs 1.2%, p=0.043), postoperative renal failure (1.6% vs 3.2%, p=0.435), postoperative sepsis (1.2% vs 0.9%), p=0.337) and postoperative hematologic complications (postoperative bleeding (9.5% vs 5.3%, p=0.037), surgical reexploration (6.0% vs 2.9%, p=0.035).and length of Intensive Care Unit (ICU) stay (6.0 days vs 5.3 days, p=0.026). Finally, we observed a statistically significant decrease in the lengths of Intensive Care Unit (ICU) stay (6.0 days vs 5.1 days, p=0.026), after implementation of the POCT system and the specific algorithm for coagulation management. There were no statistically significant group differences with respect to total hospital stay (16.7 days vs 13.5 days, p=0.076). In-hospital mortality associated with cardiac surgery also did not change (4.5% vs 2.4%, p=0.132).

Conclusion: The monitoring of hemostasis by ROTEM® in cardiac surgery, was associated with decreased incidence of allogeneic blood transfusion, clinical postoperative complications and lengths of hospital and ICU stay.

 

#3

Measuring adalimumab and infliximab trough levels from finger prick blood with a rapid point-of-care assay

Larissa Brosi, Christian Reinhard, Joana Afonso, Thomas Schuster, Christian-Benedikt Gerhold and Benjamin Ricken

BÜHLMANN Laboratories AG, 4142 Schönenbuch, Switzerland

Patients suffering from inflammatory bowel disease (IBD) can be treated with the biologics adalimumab (ADL) or infliximab (IFX). Previous studies demonstrated the usefulness of therapeutic drug monitoring (TDM) to adjust individually the patient’s biologic concentration. A hindrance for TDM are long time to result and limited access to professional laboratory equipment near the patient. Patients and clinicians would benefit from a rapid point-of-care (POC) and easy to use assay, independent of laboratory equipment. ADL and IFX lateral flow serum kits (BÜHLMANN Laboratories AG) were extended in such way that capillary blood and (EDTA) whole blood can be used as analyte matrix. Disposable capillaries are used for blood collection from finger prick and for its transfer into dropper bottles that are prefilled with chase buffer. To measure ADL or IFX levels with a BÜHLMANN Quantum Blue® Reader the mixture is then applied on a Quantum Blue® Infliximab/Adalimumab lateral flow test cassette. In a matrix agreement study spiked EDTA whole blood, whole blood without anticoagulant and capillary blood samples showed good comparability to spiked serum samples used as reference. Both POC assays revealed a bias of less than 15% at the clinical decision points for ADL (5 – 12 µg/mL) and IFX (3 – 7 µg/mL). Linearity is given over a measuring range of 1.3 – 35 µg/mL and 0.4 – 20 µg/mL, respectively. Two POC assays for the determination of ADL or IFX in capillary or whole blood samples were successfully developed which can be used by non-laboratory professionals with time to result of only 15 minutes and without the need for additional laboratory equipment. The excellent agreement to serum levels shows that the BÜHLMANN Quantum Blue® Infliximab/Adalimumab Capillary Blood assays are ideal for IFX and ADL TDM analysis in a clinician’s office or an infusion site.

 

#4

In vitro TBI: Release of brain injury biomarkers in a neurosphere model system

Ophélie Righini [a], Denis Prim [a], Céline Loussert-Fonta [b], Milica Jović [a], Luc Stoppini [b], Adrien Roux [b], and Marc E. Pfeifer [a]*

[a] Diagnostic Systems Research Group, Institute of Life Technologies, School of Engineering, University of Applied Sciences and Arts Western Switzerland (HES-SO Valais-Wallis), 1950 Sion, Switzerland.
[b] Tissue Engineering Laboratory, HEPIA HES-SO University of Applied Sciences and Arts Western Switzerland, 1202 Geneva, Switzerland

Traumatic brain injury (TBI) is one of the most frequent neurological disorders. Among all the TBIs, mild traumatic brain injuries (mTBIs), also known as “concussions”, constitute 70-90% of head injuries. [1] Since symptoms of mTBIs are often absent or not very specific, mTBIs are not always spotted with currently used diagnostic tools (CT scan or MRI). [2] As head injury might induce cellular damage in the brain leading to the release of TBI-related biomarkers in the bloodstream [2], biomarker quantification is a promising method for the detection of mTBI. To support the development of the next generation of mTBI tests, an in vitro platform was designed, to mimic and track brain injuries over time. This model is based on 3D brain cell culture derived from human induced pluripotent stem cells (iPSC), e.g. neurospheres [3], and a mechanical device allowing ejection of medium onto the neuronal tissue. Reproducing the trauma (pressure and velocity of ejection) is controlled by a microvalve. Electrochemiluminescence-based immunoassays were developed for four mTBI biomarkers to investigate the biomarker release kinetics. The assays were robust and sensitive enough, allowing the observation of significant biomarker increases 2 hours post-neurosphere injury. The analytical approach supports further studies into the exact injury kinetics and dynamics of brain cells having experienced a trauma. Ultimately, a better understanding of temporal biomarker injury profiles could enable the development of an integrated POC diagnostic device designed to detect a more comprehensive panel of mTBI biomarkers translating to a more sophisticated next generation TBI diagnosis.

[1] Azizi S, Hier DB, Allen B, et al. A Kinetic Model for Blood Biomarker Levels After Mild Traumatic Brain Injury. Front Neurol. 2021;12:668606. doi:10.3389/fneur.2021.668606

[2] Adrian H, Mårten K, Salla N, Lasse V. Biomarkers of Traumatic Brain Injury: Temporal Changes in Body Fluids. eNeuro. 2016;3(6). doi:10.1523/ENEURO.0294-16.2016

[3] Govindan S, Batti L, Osterop SF, Stoppini L, Roux A. Mass Generation, Neuron Labeling, and 3D Imaging of Minibrains. Front Bioeng Biotechnol. 2021;8:582650. doi:10.3389/fbioe.2020.582650

 

TERMS AND CONDITIONS OF POSTER SESSION FOR THE SWISS SYMPOSIUM IN POINT-OF-CARE DIAGNOSTICS 2022:

Successfully submitted abstract will be acknowledged via an e-mail with a poster number, which should be quoted in all correspondence. Allow at least 48 hours for your receipt to be returned to you.
Once the abstracts is accepted, at least one of the authors must register for and present at the symposium. Abstracts of all accepted contributions will be included within the abstract book, which will be distributed to all registered conference participants.